Isaacs JT - Search Results

1

Benzoylphenylurea sulfur analogues with potent antitumor activity.

Hallur G, Jimeno A, Dalrymple S, Zhu T, Jung MK, Hidalgo M, Isaacs JT, Sukumar S, Hamel E, Khan SR. Hallur G, et al. Among authors: isaacs jt. J Med Chem. 2006 Apr 6;49(7):2357-60. doi: 10.1021/jm051261s. J Med Chem. 2006. PMID: 16570932

2

Modified synthesis and antiangiogenic activity of linomide.

Khan SR, Mhaka A, Pili R, Isaacs JT. Khan SR, et al. Among authors: isaacs jt. Bioorg Med Chem Lett. 2001 Feb 26;11(4):451-2. doi: 10.1016/s0960-894x(00)00699-5. Bioorg Med Chem Lett. 2001. PMID: 11229745

3

Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models.

Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Denmeade SR, et al. Among authors: isaacs jt. Prostate. 2001 Jun 15;48(1):1-6. doi: 10.1002/pros.1075. Prostate. 2001. PMID: 11391681

4

Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.

Denmeade SR, Lövgren J, Khan SR, Lilja H, Isaacs JT. Denmeade SR, et al. Among authors: isaacs jt. Prostate. 2001 Jul 1;48(2):122-6. doi: 10.1002/pros.1088. Prostate. 2001. PMID: 11433422

5

Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.

Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT. Weeraratna AT, et al. Among authors: isaacs jt. Clin Cancer Res. 2001 Aug;7(8):2237-45. Clin Cancer Res. 2001. PMID: 11489797

6

Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells.

Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Jakobsen CM, et al. Among authors: isaacs jt. J Med Chem. 2001 Dec 20;44(26):4696-703. doi: 10.1021/jm010985a. J Med Chem. 2001. PMID: 11741487

7

A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer.

Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. Mhaka A, et al. Among authors: isaacs jt. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2459-61. doi: 10.1016/s0960-894x(02)00433-x. Bioorg Med Chem Lett. 2002. PMID: 12161157

8

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Denmeade SR, et al. Among authors: isaacs jt. Prostate. 2003 Mar 1;54(4):249-57. doi: 10.1002/pros.10199. Prostate. 2003. PMID: 12539223

9

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.

Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Denmeade SR, et al. Among authors: isaacs jt. J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000. doi: 10.1093/jnci/95.13.990. J Natl Cancer Inst. 2003. PMID: 12837835

10

Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase.

Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT. Singh P, et al. Among authors: isaacs jt. J Med Chem. 2005 Apr 21;48(8):3005-14. doi: 10.1021/jm049319a. J Med Chem. 2005. PMID: 15828839

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

372 results

Search Page

Filters